CLINICAL_TRIALS ClinicalTrials.gov record update

Restoration of Radioiodine Uptake with Selpercatinib in RET Fusion-Positive Radioiodine-Refractory Thyroid Cancer: a Phase 2 Study Performed in Collaboration with the International Thyroid Oncology Group (ITOG)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT05668962
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:27:03.082656+00:00
Published At: 2024-12-12T00:00:00+00:00
Record Updated At: 2024-12-12
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Thyroid Cancer", "Thyroid Carcinoma", "Metastatic Thyroid Cancer", "Follicular Thyroid Cancer", "Unresectable Thyroid Gland Carcinoma", "Papillary Thyroid Cancer"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2024-12-12"
protocolSection.identificationModule.nctId: "NCT05668962"
protocolSection.identificationModule.officialTitle: "Restoration of Radioiodine Uptake with Selpercatinib in RET Fusion-Positive Radioiodine-Refractory Thyroid Cancer: a Phase 2 Study Performed in Collaboration with the International Thyroid Oncology Group (ITOG)"
protocolSection.statusModule.overallStatus: "RECRUITING"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.